Monday November 23 2009 | Biotechnology feed | All feeds
|
|
|
Hunter-Fleming Ltd
Download detailed PDF Members: Hunter-Fleming is an innovative pharmaceutical development company, specializing in the development of radically novel therapeutics relevant to the treatment of acute and chronic inflammatory degenerative disorders - disorders with significant unmet medical needs. The Company’s initial focus is on neurodegenerative disorders of the central nervous system (CNS) and autoimmune disorders, areas in which the management has a proven track record in the successful development of novel compounds.Hunter-Fleming is building a broad, balanced portfolio of innovative development projects and technologies with leading academic groups and the pharmaceutical industry through licensing agreements, acquisitions, and in-house innovations which have already resulted in a proprietary series of 12 patent families.Through its access to enabling academic technologies, Hunter-Fleming has identified a potential for the design of novel second generation neuroprotective compounds. Hunter-Fleming has also established a joint venture (Hunter-Oncology Ltd) with Queen's University (Belfast) Cancer Centre to develop novel, innovative anti-cancer agents.
This page has been viewed 312 times since April 2007, the link to the organisation's website has been followed 63 times Search for more companies in Bristol This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for Hunter-Fleming Ltd | ||||||||||||||||||||||||||||||
|
Nothing in this website should be used in
place of personal medical advice from your own qualified medical
practitioner. |
All rights reserved. All other trademarks recognized. |
|
